echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Connoya's Claudin 18.2 ADC Receives FDA Fast Track Designation for Gastric Cancer

    Connoya's Claudin 18.2 ADC Receives FDA Fast Track Designation for Gastric Cancer

    • Last Update: 2022-05-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    On April 19, Connoya announced that its new drug CMG901 (Claudin 18.


    CMG901 is an antibody-drug conjugate targeting Claudin 18.


    CMG901 is currently undergoing a dose escalation study in patients with solid tumors to evaluate the safety and tolerability of CMG901


    Previously, Connoya has obtained FDA approval for CMG901 clinical trials in gastric cancer and gastroesophageal junction adenocarcinoma in the United States in March 2021, and received FDA orphan drug designation in April 2022


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.